Janssen Wins Push To Arbitrate Zytiga Generic Delay Suit
By Christopher Cole ( October 12, 2021, 7:45 PM EDT) -- Janssen Biotech Inc. successfully persuaded a New Jersey federal judge to rule on Tuesday that arbiters must resolve a drugstore chain's antitrust suit accusing the pharma giant of unlawfully delaying a generic form of the prostate cancer drug Zytiga....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.